Pegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centres

Basit Öğe Kaydı
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorKurtaran, Behice
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorYuksel, Esma
dc.contributor.authorOzkaya, Deniz
dc.contributor.authorTasbakan, Meltem Isikgoz
dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorDurusoy, Raika
dc.contributor.authorAksu, Hasan Salih Zeki
dc.date.accessioned2019-10-27T22:12:27Z
dc.date.available2019-10-27T22:12:27Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractIn this study, we aimed to evaluate the 1-year post-treatment follow-up results of 112 patients who received pegylated interferon (PEG-IFN) for 52 weeks. HBeAg negativity/seroconversion and/or negative HBV-DNA at the end of the treatment were considered as response. Patients who had response at the end of treatment but had HBV-DNA breakthrough during 1-year follow-up were considered as relapse. The study group comprised 112 cases (34 HBeAg-positive, 78 HBeAg-negative). In HBeAg-positive and -negative cases, end-of-treatment response rates were 2.9% and 60.2%, whereas 1-year sustained virological response rates were 0 and 33.3%, respectively. When we compared relapse cases versus cases with response at the end of 1-year follow-up, being female and having low viral load were the two parameters associated with higher response rates (Chi-square, P=0.028; Mann-Whitney U test, P=0.023). Overall non-response rates to PEG-IFN were high (57.1%). Results in HBeAg-positive cases were disappointing.en_US
dc.identifier.doi10.1179/1973947813Y.0000000152en_US
dc.identifier.endpage341en_US
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.issue6en_US
dc.identifier.pmid24171823en_US
dc.identifier.startpage339en_US
dc.identifier.urihttps://doi.org/10.1179/1973947813Y.0000000152
dc.identifier.urihttps://hdl.handle.net/11454/49439
dc.identifier.volume26en_US
dc.identifier.wosWOS:000345637500004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofJournal of Chemotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectGenotypeen_US
dc.subjectPegylated interferonsen_US
dc.subjectPrimary non-respondersen_US
dc.subjectSecondary non-respondersen_US
dc.subjectTreatment responseen_US
dc.titlePegylated interferon in HBeAg-positive and -negative chronic hepatitis B patients: post-treatment 1-year results of three Turkish centresen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu